Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sirtratumab Vedotin (ASG-15ME) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets SLITRK6 covalently linked to the potent cytotoxic agent monomethyl auristatin E (MMAE). Sirtratumab Vedotin is designed to selectively deliver the microtubule-disrupting payload MMAE to tumor cells expressing the SLITRK6 antigen, granting it significant potential for research in bladder cancer and metastatic urothelial carcinoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $198 | In Stock | |
5 mg | $619 | In Stock | |
10 mg | $993 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Sirtratumab Vedotin (ASG-15ME) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets SLITRK6 covalently linked to the potent cytotoxic agent monomethyl auristatin E (MMAE). Sirtratumab Vedotin is designed to selectively deliver the microtubule-disrupting payload MMAE to tumor cells expressing the SLITRK6 antigen, granting it significant potential for research in bladder cancer and metastatic urothelial carcinoma. |
Synonyms | Ha15-10ac12.1, Ha15-10ac12, AGS15C |
Cas No. | 1824663-82-2 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.